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Abstract
Background: High mammographic density (HMD) not only confers a significantly increased risk of breast cancer
(BC) but also is associated with BCs of more advanced stages. However, it is unclear whether BC progression and
metastasis are stimulated by HMD. We investigated whether patient-derived HMD breast tissue could stimulate the
progression of MCF10DCIS.com cells compared with patient-matched low mammographic density (LMD) tissue.
Methods: Sterile breast specimens were obtained immediately after prophylactic mastectomy from high-risk
women (n = 10). HMD and LMD regions of each specimen were resected under radiological guidance. Human
MCF10DCIS.com cells, a model of ductal carcinoma in situ (DCIS), were implanted into silicone biochambers in the
groins of severe combined immunodeficiency mice, either alone or with matched LMD or HMD tissue (1:1), and
maintained for 6 weeks. We assessed biochamber weight as a measure of primary tumour growth, histological
grade of the biochamber material, circulating tumour cells and metastatic burden by luciferase and histology. All
statistical tests were two-sided.
Results: HMD breast tissue led to increased primary tumour take, increased biochamber weight and increased
proportions of high-grade DCIS and grade 3 invasive BCs compared with LMD. This correlated with an increased
metastatic burden in the mice co-implanted with HMD tissue.
Conclusions: Our study is the first to explore the direct effect of HMD and LMD human breast tissue on the
progression and dissemination of BC cells in vivo. The results suggest that HMD status should be a consideration in
decision-making for management of patients with DCIS lesions.
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Background
Mammographic density (MD) refers to the radio-opaque
tissue on a mammogram. High mammographic density
(HMD) is associated with a higher rate of breast cancer
(BC). Indeed, women in the highest MD quartile have a
four to six times increased risk of BC compared with the
lowest quartile after adjustment for age and body mass
index (BMI), a relative risk that is second only to
BRCA1/2 gene mutation [1, 2]. It is not clear why HMD
is associated with this increased BC risk, although re-
duced MD has been associated with response to hor-
mone therapy in both prevention and treatment settings,
as reviewed by Huo et al. [3, 4]. HMD is not uncommon;
42 % of women in the 40- to 59-year-old age group and
25 % of women in the 60- to 79-year-old age group have
breasts that are at least 50 % mammographically dense [5].
Ursin and colleagues retrospectively assessed mammo-
grams taken prior to and at the time of ductal carcinoma
in situ (DCIS) diagnosis. They found that DCIS lesions
occurred primarily in areas of HMD, suggesting that
MD may stimulate BC initiation [6]. BCs that arise
within areas of HMD are more commonly associated
with factors indicative of a poor prognosis, including
large tumour size, high histological grade, lymphovascu-
lar invasion and advanced stage, as compared with those
arising within low mammographic density (LMD) [7–9].
It is not clear whether HMD increases the risk of metas-
tasis. Two studies have shown that HMD is associated
with an increased rate of local recurrence after breast-
conserving surgery, but not with distant recurrence
[10, 11]. We found that cytokeratin (CK)-positive
tumour cells in HMD connective tissue are associated
with local recurrence but not with distant metastasis
[12]. Also, we discovered that collagen matrices repre-
senting concentrations of HMD seen in ductal carcin-
oma tissues induced increased BC cell migration
compared with LMD tissue [13]. Increased stromal
collagen in mouse mammary tissue was also shown to
result in more invasive tumour phenotypes [14].
In order to assess whether HMD has any causal rela-
tionship with BC risk, we developed a biochamber
mouse model that can viably grow and maintain the MD
differential of normal breast tissue [15]. In the present
study, we used it to determine whether HMD could
stimulate the progression of DCIS-like lesions.
Methods
Sample accrual
This study was approved by the Peter MacCallum Human
Research Ethics Committee (08/21) and St Vincent’s
Hospital Melbourne Animal Ethics Committee (09/14).
Between 2014 and 2015, ten women undergoing prophylac-
tic mastectomy at St Vincent’s Hospital Melbourne pro-
vided consent through the Victorian Cancer Biobank. All
participants gave their written informed consent for tissue
accrual and publication of the study results. These women
underwent the prophylactic procedure because of con-
firmed gene mutation carrier status and/or a strong family
or past history of BC. Women were excluded from the
study if suspicious lesions were visualised by pre-operative
imaging.
Tissue handling and selection of high and low
mammographic density regions
Tissue sampling was carried out as previously described
[15–18]. In brief, immediately after mastectomy, a 1-cm
slice of breast tissue was resected from the fresh mastec-
tomy specimen in a sterile environment by breast pa-
thologists. HMD and LMD regions of the tissue slice
were identified by examining specimen radiograms. Se-
lected HMD and LMD tissues were then separately
minced with a scalpel and mixed 1:1 with BD Matrigel™
(BD Biosciences, Billerica, MA, USA) supplemented with
basic fibroblast growth factor (1 μg/ml; Sigma-Aldrich,
Sydney, Australia) using sterile technique [16].
Preparation for in vivo monitoring of MCF10DCIS.com cells
MCF10DCIS.com (DCIS.com) cells were provided by
Robert J. Pauley, Barbara Ann Karmanos Cancer Institute,
Detroit, MI, USA [19]. Luciferase/mCherry tagging
[20] of DCIS.com cells is described in Additional file 1:
Supplementary Methods. Cells were maintained in
DMEM/F-12 medium (1:1) supplemented with 5 % horse
serum and 4 mM glutamine [21, 22] in a humidified
incubator (37 °C/5 % CO2). The top 10 % of mCherry-
expressing cells were selected using flow cytometry and
propagated in vitro for a maximum of two passages in
preparation for murine chamber implantation, with or
without fresh human mammary tissue.
Murine xenograft model and ex vivo analysis of tumour
burden using bioluminescence
For all experiments, mouse care was carried out in accord-
ance with St Vincent’s Animal Ethics Committee guidelines.
Patient-paired HMD or LMD breast tissue was mixed with
1 × 105 DCIS.com cells and then suspended in Matrigel™ be-
fore being placed in the silicone chamber in the right groin
of 6 week-old female severe combined immunodeficiency
mice (n = 4 for HMD/woman, 4 for LMD/woman, 40 μl per
chamber) vascularised by the inferior epigastric pedicle, as
described previously [15, 17, 18]. As controls, 1 × 105 DCIS.-
com cells were also inserted into biochambers with Matri-
gel™ without prior mixing with any human breast tissue in
four separate mice each time a patient sample was processed
(i.e., n = 4/woman) (see Additional file 2: Figure S1).
Tissue material from the biochambers was harvested
at 6 weeks. Mice were given an intraperitoneal injection
of 150 mg/kg luciferin (Promega, Madison, WI, USA),
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placed under anaesthesia using inhaled isoflurane, had
blood drawn via cardiac puncture and then were humanely
killed after 10 minutes. Biochamber material and mouse
organs were removed and imaged ex vivo. Further details
on luciferase and mCherry/red fluorescent protein (RFP)
imaging are provided in Additional file 1: Supplementary
Methods. Following imaging, the harvested materials were
immediately fixed in 10 % neutral buffered formalin for
24 h before being transferred to 70 % ethanol for storage.
Samples were subsequently processed, embedded in paraf-
fin and sectioned at 5-μm thickness for histological and
immunohistochemical analyses.
Circulating tumour cell processing and quantification
Mouse blood was processed with red blood cell lysis buf-
fer and PBS to remove serum and bulk erythrocytes.
Further details on circulating tumour cell (CTC) pro-
cessing are provided in Additional file 1: Supplementary
Methods. The resulting pellets were then mixed with
500 μl of DCIS.com cell culture medium, and 400 μl of the
suspension were plated in 60 × 15-mm cell culture dishes
(CELLSTAR®; Greiner Bio-One GmbH, Frickenhausen,
Germany) along with additional 1.5 ml of DCIS.com cul-
ture medium. This mixture was maintained in culture for
7 days. Plates were washed with PBS prior to crystal violet
staining and inspection for mCherry-positive CTCs. Blood
from naïve mice (n = 7) was also collected, processed and
cultured as a negative control. Fluorescence microscopy
was performed (Zeiss Axio Vert.A1; Carl Zeiss Micros-
copy, Thornwood, NY, USA) to identify mCherry-tagged
DCIS.com cells. A bright-field Leica DFC425 microscope
(Leica Microsystems, Buffalo Grove, IL, USA) was then
used to image four random areas of each plate at × 20
magnification for manual counting and comparison of
CTCs. CTCs were identified using bright field microscopy
on the basis of their size and morphology that were
evident under the fluorescence microscope.
Assessment of harvested chamber tissue
Haematoxylin and eosin (H&E) staining was performed
with all biochamber explants (harvested chamber tissue)
and organ specimens in which positive luciferase and
fluorescent signals were detected. A consultant patholo-
gist (CK) who was blinded to the experimental groups
assessed the H&E-stained slides of all chamber explants
to determine the presence or absence of DCIS and inva-
sive ductal carcinoma (IDC). Invasive carcinomas, when
present, were scored for glandular differentiation, nu-
clear pleomorphism and mitotic count using the Not-
tingham grading system [23, 24].
Immunohistochemical staining
The presence of DCIS versus IDC was further confirmed
on representative slides with myoepithelial marker human-
specific p63 immunohistochemical nuclear staining (Dako
M7247, clone 4A4; Dako, Carpinteria, CA, USA) [25, 26].
Numerical categories were assigned to the histological
results for comparisons among the three groups. These
details are given in Additional file 1: Supplementary
Methods. Tissue sections were photographed at × 10
and × 20 magnification using an AxioVision microscope
(Carl Zeiss Microscopy).
To confirm metastases in luciferase-positive organs that
did not show clear evidence of cancer on H&E stains, we
sectioned the entire paraffin tissue block and stained con-
secutive sections with human-specific antibodies against
cytokeratin 5 (CK5) (NCL-CK5, clone XM26; Leica Bio-
systems, Buffalo Grove, IL, USA) [27, 28] and DNA repair
protein Ku70 (ab58150; Abcam, Cambridge, MA, USA)
[29, 30]. Details regarding Ku70 and CK5 staining are
provided in Additional file 1: Supplementary Methods.
Statistical analyses
For each of the ten women, four mice were used for
each of the DCIS.com +HMD, DCIS.com + LMD and
DCIS.com-only groups. The mean value of all four mice
from each experimental group was calculated and used as
a representative value for that woman. HMD+DCIS.com,
LMD+DCIS.com, and DCIS.com-only groups were com-
pared using patient-matched (paired) one-way analysis of
variance and Tukey’s multiple comparisons test using
GraphPad Prism® version 6.00 for Windows software
(GraphPad Software, La Jolla, CA, USA). Prior to all ana-
lyses, normality tests were used to confirm whether para-
metric tests were appropriate. The Grubbs test was used
to detect any significant outliers for each set of data before
it was analysed. All statistical tests were two-sided. Error
bars in all graphs indicate SEM, and a P value <0.05 was
considered to be statistically significant.
Results
Demographic characteristics of study participants
Our cohort of mammary tissue donors comprised a group
of pre-menopausal and post-menopausal women with a
mean age of 45 years. Six of them had confirmed gene
mutation carrier status. The other four women underwent
prophylactic mastectomy because of a significant past or
family history of BC. Breast Imaging-Reporting and Data
System (BI-RADS) scores ranged from 1 to 4 across the
cohort. The demographic characteristics of the cohort are
summarised in Table 1.
Analyses of weights and histopathology of chamber
explant materials
The mean weights of biochamber materials from the
HMD+DCIS.com group (n = 4 mice/patient) were on
average two times greater than those in the DCIS.com-only
(n = 4 mice/patient) and DCIS + LMD (n = 4 mice/patient)
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groups (Fig. 1). Biochamber weights from the HMD+
DCIS.com group were significantly greater than those in
the LMD+DCIS.com group (P = 0.002), but they were not
significantly greater than those in the DCIS.com-only
group. Explant weights from the LMD+DCIS.com group
tended to be less than those in the DCIS.com-only group,
but this difference was not statistically significant (Fig. 1).
The histology of the biochamber materials contained
benign mammary tissue, high-grade DCIS lesions only
or high-grade DCIS with grade 3 IDC (Fig. 2a–d). p63
staining showed that the myoepithelial layer remained
intact in normal mammary ducts as well as in DCIS le-
sions; however, this integrity was lost in IDC, despite
tumour cells staining positive with p63 because of their
basal phenotype (see Additional file 3: Figure S2). The
percentage of high-grade DCIS with grade 3 IDC in the
HMD +DCIS.com group was higher than in both the
DCIS.com-only and LMD +DCIS.com groups for nine
of ten women (Fig. 2e). When we compared the mean
values of all ten women, we observed that the HMD +
DCIS.com group had a significantly higher proportion of
high-grade DCIS and grade 3 IDC than the other groups
(Fig. 2f ). In the presence of LMD tissue, the resulting
percentage of high-grade DCIS and grade 3 IDC was
often lower than in the DCIS.com-only group; however,
this trend was not statistically significant.
Luciferase signal and tumour burden
Both luciferase and mCherry images were collected for
the first three accruals, and the results were comparable
(Additional file 4: Figure S3). Hence, only biolumines-
cence images were used for analyses thereafter. HMD +
DCIS.com biochambers showed significantly higher
bioluminescent signalling than the LMD +DCIS.com
group (P = 0.005). Interestingly, the LMD +DCIS.com
group also showed a significant reduction in biolumines-
cent signalling compared with the DCIS.com-only group
(P = 0.03) (Fig. 3).
Comparison of ‘take’ rates of MCF10DCIS.com cells in
biochambers
For each woman, the ‘take’ rate was assessed as the propor-
tion of mice in each experimental sub-group (n = 4) that
had a positive DCIS.com presence after 6 weeks as con-
firmed by IVIS in vivo imaging and histology (PerkinElmer,
Table 1 Demographic characteristic of study participants
(n = 10)
Selected characteristics Number or mean
Age at surgery date Mean 45 years, median 43 years,
range 31–64 years
BI-RADS score, n
4 2
3 2
2 4
1 2
Risk factors (some women had more than one risk factor)
Strong family history 6
BRCA1 mutation-positive 2
BRCA2 mutation-positive 3
PTEN mutation-positive 1
Past history of BC or DCIS 7
Menopausal status
Pre-menopausal 5
Peri-menopausal 2
Post-menopausal 3
Parity
Parous 8
Nulliparous 2
Abbreviations: BI-RADS Breast Imaging-Reporting and Data System, BC Breast
cancer, IDC Invasive ductal carcinoma, DCIS Ductal carcinoma in situ
BI-RADS score 1 = predominantly fat, 2 = scattered fibroglandular densities,
3 = heterogeneously dense, 4 = extremely dense
Fig. 1 Quantitative analyses of chamber explant weights. a Coloured bar graphs show patient-matched DCIS-only (blue), DCIS + HMD (red) and
DCIS + LMD (green) comparisons of chamber explant weights for all ten women. b Average values for each woman are shown as scatterplots.
HMD High mammographic density, LMD Low mammographic density, DCIS MCF10DCIS.com cells. **P = 0.002. All bar and scatterplot graphs
represent mean + SEM
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Waltham, MA, USA). The HMD+DCIS.com group was
the only group to have a 100 % take rate, while the DCIS.
com-only and LMD+DCIS.com groups had 82.5 % and
70.0 % take rates, respectively (n = 10 women) (Fig. 4).
Comparison of tumour metastasis in DCIS.com + HMD,
DCIS.com + LMD and DCIS.com-only groups
Cancer metastases were detected by ex vivo biolumines-
cence imaging most frequently in axillary lymph nodes
and lungs, and occasionally in the liver and/or bowel.
Areas with positive luciferase signals were dissected and
stained with H&E for histological confirmation of metas-
tasis (Fig. 5a1, a2). Occasionally, small clusters of cancer
cells were visualised by imaging (arrow in Fig. 5b1), but
they were not readily identified upon H&E staining. In
those cases, human-specific CK5 and Ku70 staining con-
firmed the presence of tumour cells of human origin
(Fig. 5b1–b3).
The number of organs with cancer metastases was
counted per mouse for each group (Fig. 6a). The HMD+
DCIS.com group had significantly higher mean numbers
of metastasis-positive organs than the LMD+DCIS.com
group across all ten women (P = 0.0234) (Fig. 6b). The
mean quantities of bioluminescent signalling in metasta-
ses were significantly increased in the HMD+DCIS.com
compared with the LMD+DCIS.com group (P = 0.008)
(Fig. 6c and d). As an alternate representation of the data,
the heat map shown in Fig. 7 depicts that mice implanted
with HMD+DCIS.com tissue had higher frequencies and
amounts of distal metastatic burden.
To assess the levels of CTCs, mouse blood was col-
lected from nine of the ten independent experiments
and cultured for 7 days. CTCs of approximately 50 μm
in diameter that were mCherry-positive and stained with
crystal violet were detected in the blood samples from
all nine accruals (Fig. 8). By contrast, there were no simi-
larly sized colonies present in cultures generated from
Fig. 2 Quantitative analysis of the histopathological results of chamber material. a–d Representative photomicrographs of the various numerical
categories used to score human breast histopathology observed in biochambers. a Category 0, the absence of DCIS and cancer and the presence
of fatty normal breast tissue. b Category 0, the absence of DCIS and cancer and the presence of dense normal breast tissue. c Category 1, high-
grade DCIS only. d Category 2-3, grade 3 invasive carcinoma. e The numerical histological categories 0–3 included a breakdown of the presence
of high-grade DCIS alone or along with a certain percentage of grade 3 IDC. The mean histological category for the chamber explants for each of
the ten women according to the type of input material. f Average values for each woman for the histological category of the chamber material.
HMD High mammographic density, LMD Low mammographic density, DCIS MCF10DCIS.com cells, IDC Invasive ductal carcinoma. *P = 0.004;
**P = 0.002. All bar and scatterplot graphs represent mean ± SEM
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tumour-naïve mice. These cultures also lacked mCherry
signalling and crystal violet staining. The number of CTCs
per mouse was counted and adjusted for the volume of
blood collected. When averaged per patient, the number
of CTCs per millilitre was not significantly increased in
the HMD+DCIS.com group compared with the LMD+
DCIS.com group (P = 0.0876) (Fig. 8).
Correlation between participant demographics and
DCIS.com cellular responses
When assessing the chamber responses of patient-matched
HMD+DCIS.com, LMD+DCIS.com and DCIS.com-alone
groups according to individual women’s demographic
characteristics (see Additional file 5: Figure S4), we found
that the results from post-menopausal women (patients 3,
4 and 7, all of whom were parous and known to be
gene mutation-negative and had overall non-dense
breasts [BI-RADS scores 2 and 1]) did not differ from
those of pre-menopausal women (n = 7) in terms of mean
histological categories and CTCs. However, the mean cham-
ber explant weight, luciferase signalling and metastases from
HMD tissue of patient 3 were all lower than corresponding
parameters of the DCIS.com-alone group, which may have
been due to variations in the DCIS.com cells alone. These
results from patient 7 followed the overall trend of the
HMD group being associated with increased tumour
growth. When we compared the chamber responses from
breast tissues of gene mutation carrier-positive women (pa-
tients 1, 2, 4, 5, 9 and 10) with those of gene mutation-
negative women (patients 3, 6, 7 and 8), and between
women with overall dense breasts (BI-RADS score 3 or 4:
patients 2, 6, 8 and 9) and women with overall non-dense
breasts (BI-RADS score 1 or 2: patients 1, 3, 4, 5, 7 and 10),
we found no significant differences. Furthermore, nullipar-
ous women (patients 8 and 10) did not show a different
trend with regard to chamber outgrowth weights or histo-
logical results. Both women had elevated numbers of CTCs
in their HMD group, although no metastasis was found in
mice for patient 10, and the number of metastasis-positive
organs in the tissue groups of patient 8 was lower than that
of the DCIS.com-alone arm (Additional file 5: Figure S4d–f).
Overall, the finding of increased tumour growth and
dissemination associated with the HMD+DCIS.com group
as compared with the other two groups did not differ signifi-
cantly by age, menopausal status, gene mutation carrier
status, overall breast BI-RADS category or parity. Future
studies with larger study cohorts are needed to provide suffi-
cient power for assessing whether the pro-malignant effect
of HMD is modulated by any of the aforementioned factors.
Discussion
In this within-individual matched-sample study, we found
that HMD breast tissue led to significantly increased
tumour weight, greater proportions of high-grade DCIS
and grade 3 IDCs, and metastasis of DCIS.com cells
Fig. 3 Analyses of chamber explant luciferase signalling. a Luciferase signal measured in the chambers at explant (×108 photons per second) for
each of the ten women. b Average values for each woman are shown as scatterplots after removal of a significant outlier (patient 6). HMD High
mammographic density, LMD Low mammographic density, DCIS MCF10DCIS.com cells. *P = 0.03; **P = 0.005. All bar and scatterplot graphs
represent mean ± SEM
Fig. 4 Comparison of chamber ‘take’ rates representing the viability of
input MCF10DCIS.com cells. The average number of positive biochambers
(contained a histological category of at least 1: DCIS material only) as a
percentage of the total number of chambers implanted. HMD High
mammographic density, LMD Low mammographic density, DCIS
MCF10DCIS.com cells. **P= 0.008. Error bar indicates SEM
Huo et al. Breast Cancer Research  (2016) 18:106 Page 6 of 13
compared with LMD tissue from the same woman. The
tumour-promoting effect of HMD was observed across
women, despite the heterogeneous demographic charac-
teristics of our cohort (mixed menopausal statuses and
risk profiles). The finding of high-grade DCIS with grade
3 IDC was consistent with the characteristics of DCIS.com
cells to form high-grade DCIS that progresses to corres-
pondingly high-grade IDC in vivo [22]. To our knowledge,
we are the first to demonstrate a causal relationship
between HMD tissue and BC progression and metas-
tasis in an in vivo setting. We also found a trend of
increased CTCs in mice carrying biochambers im-
planted with HMD tissue compared with LMD and
DCIS.com only; however, this was not statistically sig-
nificant, which may be due to the variation in CTC
numbers per mouse for each woman and between
women, as well as to our small sample size.
There is little evidence on whether HMD directly af-
fects the progression and metastasis of already estab-
lished tumours; however, the pathobiology of HMD does
support stimulated cancer progression [16, 31]. Boyd
and colleagues found that HMD is associated with in-
creased breast tissue stiffness [31], and HMD stroma
has increased collagen organisation compared with
LMD from the same woman [16, 32, 33]. Specifically,
McConnell and colleagues found that increased colla-
gen stiffness and organisation, not abundance, corre-
lated with HMD in a cohort of 22 post-menopausal
women (4 cancer-free and 18 with BC). In their
study, the tissues from 18 women were sampled at
least 4 cm away from tumours, albeit within the same
breasts where cancer had initially arisen, and a total
of 6 HMD samples were compared with 6 LMD tis-
sue specimens of different women matched for age
and menopausal status, but not for BMI or other
confounding factors [32]. Their findings contrast with
our earlier association of HMD with increased stroma
and collagen content [16], where paired HMD breast
tissue showed increased collagen organisation as well
as abundance compared with LMD tissue of the same
woman in a group of 15 cancer-free women. As
McConnell et al. used Picrosirius red staining and
atomic force microscopy, whereas we used second
harmonic generation imaging coupled with grey-level
co-occurrence matrix analysis; variable methodologies
may also contribute to the differences in the results.
Collagen of altered alignment, through mechanical
and other unknown properties, have been shown to
facilitate tumour growth [14, 34, 35]. The breast
stroma is a rich source of numerous cell types,
Fig. 5 Representative images of tumour metastasis obtained by imaging and histology. a1 and a2 Images from the same mouse lymph node.
b1–b3 Images illustrate the lymph node of a different mouse. a1 The white arrow indicates a luciferase (luc) signal in a mouse lymph node. a2
Haematoxylin and eosin staining of the luc-positive lymph node from a1. b1 The white arrow indicates a luc signal in a mouse lymph node. b2
Human-specific CK5 staining of the luc-positive lymph node from b1; CK5-positive cells are stained brown. b3 Human-specific Ku70 staining of
the luc-positive lymph node from b1. Ku70-positive cells are stained yellow. Scale bar = 10 μm
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including fibroblasts, adipocytes and extracellular
matrix (ECM) proteins [36–38]. ECM comprises not
only collagen but also fibronectin, proteoglycans and
matrix metalloproteinase (MMP) inhibitors, which
have also been shown to enhance collagen stiffness
and regulate growth factors and susceptibility to BC
[3, 39–43]. Although BC is of epithelial cell origin
and HMD is associated with increased benign epithe-
lial lesions [44, 45], an increasing body of data sup-
ports the hypothesis that perturbations in stromal
architecture are key to establishing a pro-neoplastic
environment that enhances cancer growth [46, 47].
In addition, fibroblasts are a major stromal compo-
nent and have been implicated in pro-malignant ac-
tivity through the production and/or modification of
cytokines, growth factors, ECM components and
MMPs [48, 49].
Our results show that the incorporation of LMD
breast tissue into DCIS.com cell inoculations reduced
tumour weight, lowered the proportion of high-grade
DCIS with grade 3 IDCs and led to less metastasis
compared with incorporating HMD tissue, suggesting
a protective role of the adipose-rich, dense, connective
tissue-poor LMD tissue. Consistent with the trends and
effects seen in our studies, the association of absolute
dense area with BC risk was found to be decreased for lar-
ger breasts [50]. Investigators in two large case-control
studies (634 cases:1880 controls [51] and 1424 cases:2660
controls [52]) and a prospective study of 111 cases of BC
[53] all found statistically significant inverse associations
of non-dense breast area with BC risk. There is limited
evidence on how adipose tissue modifies BC risk and can-
cer progression. Fatty breast tissue secretes leptin, which
was found to enhance BC cell proliferation, as well as adi-
ponectin, which limits cell proliferation and promotes
apoptosis of aberrant cells [54]. Whilst it is unknown
whether adipose tissue produces more adiponectin than
leptin, a balance between the two was proposed to alter
BC risk [55]. Adipose tissue also stores vitamin D, known
for its protective effect against cancer development
through a wide range of roles, including cell-cycle arrest,
apoptosis, repair and promotion of differentiation
[56–58]. Little is currently known about cancer-
associated adipose tissue, although it is known to secrete a
range of cytokines (interleukin [IL]-6, IL-8, chemokine [C-
C motif] ligand 5) and collagen VI, promoting BC
progression and metastasis [59–63]. Further work on
cytokines and ECM from HMD and LMD tissue is
Fig. 6 Quantitative analyses of metastases in terms of metastasis-positive organ numbers and luciferase signalling. a Coloured bar graphs of the
mean value of all four mice for each group for mean metastasis + organ numbers. b Averaged values of the mean number of metastasis-positive
organs for each woman according to the type of input material. c Coloured bar graphs of the mean level of luciferase in metastasis-positive
organs (×105 photons/second). d Averaged values of the mean luciferase load in metastasis for each woman. HMD High mammographic density,
LMD Low mammographic density, DCIS MCF10DCIS.com cells. *P = 0.02; **P = 0.008. All bar and scatterplot graphs represent mean ± SEM; triangles
indicate data value of 0
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required to understand the relationship of the de-
creased adipose content in HMD and BC.
Strengths and limitations
Previous work conducted by Chew and colleagues
showed that human HMD and LMD breast tissues that
were sampled from prophylactic mastectomy specimens,
mechanically minced, mixed with Matrigel™ and then in-
cubated in murine biochambers for 6 weeks remained
viable, maintained their original histological characteris-
tics and their MD status [15]. H&E, Masson’s trichrome
blue and vimentin staining showed increased collagen
and stromal content and a lower fat percentage in
HMD chamber tissue compared with that in LMD,
correlating with the histological composition of the
original mastectomy specimens. Thus, we believe that
mechanical mincing in preparation for chamber im-
plantation and supplementation with Matrigel™ did
not have a significant impact on the histological
composition or collagen content of implanted tissues,
and that any effect would be equally distributed to
both HMD and LMD groups. In addition, we have un-
published work showing that, when the ECM structure
is disrupted through collagenase, hyaluronidase and
trypsin digestion of the samples, the original histology
and MD status of the input material was not
maintained in murine chambers [64]. Prior to chamber
implantation, second harmonic generation imaging found
that HMD breast tissue had a higher degree of stromal
collagen organisation than LMD tissue [16]. However, fu-
ture studies are needed to further assess whether mincing
and addition of Matrigel™ would affect the mechanical
stiffness, composition or actions of MMPs in the
ECM of implanted breast tissue. Another potential
limitation of our study is that our group of ten
women was relatively young (mean age 45 years), and
five of them were pre-menopausal. The results there-
fore cannot be directly extrapolated to the average
Fig. 7 Heat map of metastasis profile for each woman. The degree of metastasis is depicted using filled blue squares to denote metastasis-positive
organs, and the level of metastatic burden is shown using the colour code shown. Patients 1–10 are shown in rows. For each woman, four mice
were implanted with DCIS alone, four with DICS + HMD and four with DCIS + LMD. The grouped columns represent the types of cells implanted,
and the sub-columns represent the site of metastatic burden. The numbers in boldface type at the beginning of each row represent the chamber
explant weight to show the correlation between chamber weight and metastasis. Inside each bar, the luciferase levels in photons per second
are indicated
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population, in particular for post-menopausal women.
However, studying normal breast tissue of different
MDs enabled us to examine features of MD that may
elevate BC risk prior to established tumour burdens
in the breast. The within-individual study design also
allowed us to compare HMD and LMD breast tissues
of the same patient, eliminating all important con-
founding factors, such as age, BMI and menopausal
status, which can be difficult to adjust for in across-
patient studies.
Conclusions
To the best of our knowledge, this study is the first
to demonstrate the direct effects of HMD and LMD
human breast tissue on the growth and dissemin-
ation of BC cells in vivo. Further studies on stromal
and ECM components will improve understanding of
BC evolution and help to identify potential biological
markers and therapeutic targets for more individua-
lised management of patients with, or at high risk
for, BC. Our data suggest a benefit of including the
Fig. 8 CTC analyses. a Representative photomicrographs under bright field of CTCs isolated and cultured blood from mice blood. b
Corresponding fluorescence image to demonstrate RFP tagging in CTCs. c Representative photomicrographs of CTCs after crystal violet staining.
d–f As negative controls, blood taken from naïve mice was also processed and cultured, and images were obtained to show the absence of
CTCs. g Coloured bar graphs of the mean value of all four mice for each group for CTC numbers. h Averaged values of the mean number of
CTCs for each woman according to the type of input material. CTC Circulating tumour cell, HMD High mammographic density, LMD Low
mammographic density, DCIS MCF10DCIS.com cells, RFP Red fluorescent protein. All bar and scatterplot graphs represent mean ± SEM.
Scale bar = 50 μm
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MD status in the assessment and therapeutic man-
agement of BC and DCIS.
Additional files
Additional file 1: The murine xenograft model Schematic diagrams
illustrate the use of 12 SCID mice associated with each woman’s tissue
accrual and the allocation of 4 mice into HMD, LMD and DCIS.com only
groups. HMD: high mammographic density; LMD: low mammographic
density; DCIS.com: MFC10DCIS.COM cells. (DOCX 16kb)
Additional file 2: Figure S1. The murine xenograft model. Schematic
diagrams illustrate the use of 12 SCID mice associated with each patient’s
tissue accrual and the allocation of 4 mice into DCIS.com + HMD,
DCIS.com + LMD and DCIS.com-only groups. The schematic mouse
shows a silicone chamber inserted in the groin with chamber material
(in grey) vascularised by the inferior epigastric pedicle (in red). HMD High
mammographic density, LMD low mammographic density, DCIS.com
MFC10DCIS.com cells. (TIF 537 kb)
Additional file 3: Figure S2. p63 immunohistochemical nuclear staining.
a Representative photomicrograph of punctate brown nuclear staining with
p63 of normal human mammary glands adjacent to invasive tumour cells
from a chamber explant at × 10 original magnification. b Normal mammary
ducts shown in (a) at × 20 original magnification. c Representative
photomicrograph of punctate brown nuclear staining with p63 of a ductal
carcinoma in situ lesion from a chamber explant at × 10 original
magnification. d Ductal carcinoma in situ lesion shown in (c) at × 20 original
magnification. e Representative photomicrograph of punctate brown
nuclear staining with p63 of invasive ductal carcinoma adjacent to ductal
carcinoma in situ lesions at × 10 original magnification. f Invasive ductal
carcinoma cells adjacent to ductal carcinoma in situ lesions shown in (e)
at × 20 original magnification. (TIF 7517 kb)
Additional file 4: Figure S3. Comparison of luciferase and mCherry
imaging. a Representative luciferase imaging of three chamber explants.
b Representative mCherry imaging of the same chamber explants shown
in a. (TIF 2371 kb)
Additional file 5: Figure S4. Correlation between participant
demographics and DCIS.com cellular responses. The table outlines the
individual demographic characteristics of each patient (n = 10). a
Coloured bar graphs show patient-matched DCIS.com only (blue),
DCIS.com + HMD (red) and DCIS.com + LMD (green) comparisons of
chamber explant weights (a), chamber explant luciferase signals (b),
mean histological category of chamber explants (c), mean number of
CTCs/ml (d), mean number of metastasis-positive mouse organs (e) and
mean luciferase signals for total metastases (f) for each patient. HMD
high mammographic density, LMD low mammographic density, DCIS
MCF10DCIS.com cells, CTC circulating tumour cells, BC breast cancer, +
positive, N/A Not available. Triangles indicate data value of 0. BI-RADS
score 1 = predominantly fat, 2 = scattered fibroglandular densities,
3 = heterogeneously dense, 4 = extremely dense. (PPTX 500 kb)
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